🔎 Trials Near Me

Home › Eye Care › Florida

Eye Care clinical trials in Florida

7 studies for Eye Care are looking for participants at sites in Florida.

Cities in Florida

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

  • Adverum Clinical Site 124, Deerfield Beach
  • Adverum Clinical Site 184, Deerfield Beach
  • Adverum Clinical Site 176, Fort Lauderdale
  • and 10 more
RecruitingPhase 3
Ages 50 and older · All sexes · Updated Sep 24, 2026 · NCT07482176

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

  • Adverum site 124, Deerfield Beach
  • Adverum site 176, Fort Lauderdale
  • Adverum site 168, Jacksonville
RecruitingPhase 2
Ages 50 and older · All sexes · Updated Aug 5, 2026 · NCT07630649

Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye

  • Bascom Palmer Eye Institute, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 24, 2026 · NCT07413172

Stem Cell Ophthalmology Treatment Study II

  • MD Stem Cells, Coral Springs
Recruiting
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT03011541

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

  • University of Miami - Bascom Palmer Eye Institute, Miami
RecruitingPhase 3
Ages 6 and older · All sexes · Updated Jun 25, 2026 · NCT06891443

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

  • Baxis Site 34, Delray Beach
  • Baxis Site 11, Lake Worth
  • Baxis Site 37, Largo
  • and 5 more
RecruitingPhase 3
All ages · All sexes · Updated Mar 17, 2026 · NCT06911424

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

  • Bascom Palmer Eye Institute, Miami
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Feb 25, 2025 · NCT06112340

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.